The FDA says it conducted an assessment of Johnson & Johnson (JNJ -0.2%) and Boehringer...

The FDA says it conducted an assessment of Johnson & Johnson (JNJ -0.2%) and Boehringer Ingelheim's Pradaxa using insurance claims and administrative data from its safety surveillance program, and found no evidence that the drug increased risk of bleeding when compared with warfarin. The agency launched an investigation of Pradaxa - which is approved to reduce the risk of stroke and embolism in patients with atrial fibrillation - last year after receiving reports of serious bleeding events in patients using the drug.

From other sites
Comments (3)
  • tampabay
    , contributor
    Comments (459) | Send Message
    A PA, physicians Asst. gave me good advice when pradaxa first came out I asked him about switching from warfarin...He Said, "let others be the ginny pigs, if its any good you will know soon enough,just stay on warfarin for now." Thanks buddie..
    2 Nov 2012, 02:08 PM Reply Like
  • DC from SC
    , contributor
    Comments (5) | Send Message
    J&J markets Xarelto, an anti-clotting drug that competes with Pradaxa; to the best of my knowledge, J&J has nothing to do with the discovery, development, or marketing of Pradaxa.
    2 Nov 2012, 06:40 PM Reply Like
  • jpate
    , contributor
    Comments (12) | Send Message
    Trial lawyers still have lots of TV advertisements! ---- Creating extreme anxiety among the public "...untreatable. You may die!! etc."
    Are they liable when a frightened patient stops their drugs and has a stroke as a result? Don't bet on it!
    2 Nov 2012, 07:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs